JPS5847497A - Preparation of 5-hydroxymethylcytosine - Google Patents

Preparation of 5-hydroxymethylcytosine

Info

Publication number
JPS5847497A
JPS5847497A JP14717481A JP14717481A JPS5847497A JP S5847497 A JPS5847497 A JP S5847497A JP 14717481 A JP14717481 A JP 14717481A JP 14717481 A JP14717481 A JP 14717481A JP S5847497 A JPS5847497 A JP S5847497A
Authority
JP
Japan
Prior art keywords
culture
hydroxymethylcytosine
medium
cytosine
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP14717481A
Other languages
Japanese (ja)
Other versions
JPS6360997B2 (en
Inventor
Takashi Suzuki
鈴木 節士
Hidekazu Sawada
沢田 秀和
Shunichi Akiyama
秋山 峻一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP14717481A priority Critical patent/JPS5847497A/en
Publication of JPS5847497A publication Critical patent/JPS5847497A/en
Publication of JPS6360997B2 publication Critical patent/JPS6360997B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PURPOSE:To collect the titled substance formed and accumulatd in a culture, by cultivating a bacterium belonging to the genus Streptoverticillium capable of producing the titled substance in a medium containing a cytosine derivative. CONSTITUTION:>=0.5mM Cytosine derivative such as cytosine, 5-halogenocytosine, 5-alkylcytidine, etc. shown by the formula (R is H, halogen or lower alkyl) is added to a medium containing a carbon source to be assimilated by a bacterium, nitrogen source, inorganic salt, a very small amount of an effective substance. A bacterium such as Streptoverticillium rimofaciens belonging to the genus Streptoverticillium, capable of producing 5-hydroxymethylcytosine is cultivated in the medium. A mold is removed from the culture, and the desired 5-hydroxymethylcytosine is obtained from the supernatant liquid using an adsorbent, solvent, etc.

Description

【発明の詳細な説明】 本発明は醗酵法による6−ヒドロキシメチ)vyシトシ
ン製造法に関する。本発明者らはスFレプトパーティy
yウム属−の代諸産物について種々研究を重ねた結果、
ストレプトパーティシリウム属菌を培地に培養すると、
6−ヒドロキシメチルシトシンが生成蓄積されること、
と夛わけ式(式中、Rは水素、ハロゲン原子または低級
アルキル基を示す]で表わされるシトシン誘導体を含有
する培地を用いると、その生成量が顕著に増大すること
を見い出し本発明を完成するに至った。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing 6-hydroxymethy)vycytosine by a fermentation method. The inventors
As a result of various studies on various products of the genus Yu,
When Streptparticillium bacteria are cultured in a medium,
6-hydroxymethylcytosine is produced and accumulated;
The present invention has been completed by discovering that when a culture medium containing a cytosine derivative represented by the following formula (wherein R represents hydrogen, a halogen atom, or a lower alkyl group) is used, the amount of cytosine produced increases significantly. reached.

[来5−1:ドロキVメチ〜シトシンは、パVメ) 9
 y * iμデイオマイVンなどの抗生物質の分子を
構成する要素として見い出されているほか、大腸菌感染
性チー偶数系ファージのデオキシリボ核酸の構成塩基成
分として存在することが知られているにすぎないので、
これを充分量入手することはきわめて困雌であった。本
発明の方法によれば、6−ヒドロキシメチルシトシンを
微生物の培養液中K[接生成蓄積させることができるの
で、容易かつ充分量の6−ヒドロキシメチA/!/)シ
ンを入手することができる。このようにして得られた6
−ヒドロキシメチfi/VトVンは1紀の抗生物質生成
の中間体として重要であるばかりか遺伝あるいはガンの
研究にとってきわめて応用範囲の広い生化学試薬として
供せられる。
[Next 5-1: Doroki V Mechi~Cytosine is Pa V Me) 9
It has been found as an element constituting the molecules of antibiotics such as y*iμ deiomycin, and is only known to exist as a constituent base component of the deoxyribonucleic acid of E. coli-infecting Qi even-numbered phages. ,
It was extremely difficult to obtain a sufficient amount of this. According to the method of the present invention, 6-hydroxymethylcytosine can be accumulated in the culture solution of microorganisms by catalytic formation, so that a sufficient amount of 6-hydroxymethyA/! /) Shin can be obtained. 6 obtained in this way
-Hydroxymethycin is not only important as an intermediate in the production of primary antibiotics, but also serves as a biochemical reagent with an extremely wide range of applications in genetic and cancer research.

本発明に用いられる微生物としては、細胞内または細胞
外に5−ヒドロキシメチルシトシン生成活性を有するス
トレプトパーティシリウム属菌はすべて使用できる。た
とえばストレプトパーティシリウム・リモファシエンス
(UFO18692)は本発明実施の目的にもつとも有
効に用いられるVS*の一例である。この菌は、バーシ
ーズ・マニュアル・オプ・デターミネーテイプ・パクテ
リオロジー第7版(Bergey’s  Manual
 of Deter−minatiVe  Bacte
riology7th EcLi、tion )におけ
る分類基準に従い、ストレプトミセス・リモ77シx 
ンス(Streptomyces  rimofaci
、ens、)と同定された(特開昭5O−126892
)が、その後、分類基準が改訂され、バーシーズ・マニ
ーユアμmオグやデターミネーテイグ・バクテリオロジ
ー第8版(1974年)に従い、水筒はストレアドパ−
ティシリウム属に属すべきものとなっ九(ザ句ジャーナ
ル・オグ・アンティビオチフス“The Journa
l  of  AntiMotics”、第81巻、第
6号、511〜618頁]。本繭株は、工業技術院微生
物工業研究所にi?ERM P Ha−2549として
、財団法人発酵研究所に工F0 18692として、ジ
・アメリカン・タイプ・カルチャー9コレクシ厘ン(T
he Ameri、can Type Cu1ture
Collection、 U、S、A )4CA T 
CCa 1120として、それぞれ寄託されている。こ
のような菌は、一般的性状として―宇土の性質あるいは
生理学上の性質が容易KffiMするので、人工的にも
自然的にも種々の変異株が容易に得られるが、これらの
変異株も6−ヒドロキシメチルシトジンの生成活性を失
っていないかぎシ、本発明の目的に使用することができ
る。このような変異株の例としては、工業技術院微生物
工業研究所にFERM P&−6062として、財団法
人発酵研究所に工F014125としてそれぞれ寄託さ
れているストレプトパーティシリウム・リモファシェン
ス(5treptOVert:LOlllium  r
imofaciens)(工F0 14125)株が挙
げられる。
As the microorganisms used in the present invention, all Streptparticillium genus bacteria having intracellular or extracellular 5-hydroxymethylcytosine producing activity can be used. For example, Streptparticillium rimofaciens (UFO18692) is an example of VS* that can be effectively used for the purpose of implementing the present invention. This bacterium is described in Bergey's Manual of Determinative Pacteriology, 7th Edition.
of Deter-minatiVe Bacte
Streptomyces limo77x according to the classification criteria in riology7th EcLi, tion)
Streptomyces rimofaci
, ens, ) (Japanese Patent Application Laid-Open No. 5O-126892
), but the classification criteria were subsequently revised, and water bottles were classified as stored per-
Antibiotyphoid fever should belong to the genus Tycilium.
of AntiMotics, Vol. 81, No. 6, pp. 511-618]. This cocoon strain was transferred to the Agency of Industrial Science and Technology, Microbial Research Institute, as i?ERM P Ha-2549, and to the Fermentation Research Institute, Japan, as F0 18692. As The American Type Culture 9 Collection (T
he Ameri, can Type Culture
Collection, U, S, A)4CAT
CCa 1120, respectively. Since the general properties of such bacteria are easily KffiM, various mutant strains can be easily obtained both artificially and naturally. -Kagish that has not lost its hydroxymethylcytosine production activity can be used for the purpose of the present invention. Examples of such mutant strains include Streptparticillium rimofaciens (5treptOVert: LOllium r
imofaciens) (Engineering F0 14125) strain.

本変異株を得るための具体的方法は次のとおシである。The specific method for obtaining this mutant strain is as follows.

無菌箱内に80ワツトの紫外線灯を設置し、803下方
において親株の胞子懸濁液を攪拌しながら90秒の紫外
線照射(波長2sayX)を行う。仁の芦外線照射され
た胞子懸濁液を放線菌の生育に通常用いられるスターチ
無砿塩寒天培地に拡布して、生育してきた変異株コロニ
ーよシ得られたものである。本変異株は親株に比較して
コロニーの形態が平滑であ)、その色調が淡いという特
徴を有する。また遺伝子操作技術を用いて、ストレプト
パーティシリウム・リモファシェンス(工F0 1a6
92)の5−ヒドロキシメチルシトシン生成活性を支配
している遺伝子を、大腸菌等の放線菌以外の細菌、また
は酵母に遺伝子クローニングを行い、これらの細菌また
は酵母に6−ヒドロキシメチルシトシン生成活性を有せ
しめる場合においては、とれらの微生物も本発明実施の
目的に用いることができる。
An 80 watt ultraviolet light lamp is installed in a sterile box, and the spore suspension of the parent strain is irradiated with ultraviolet light for 90 seconds (wavelength: 2sayX) under 803 while stirring. This is a mutant colony that grew by spreading a suspension of spores that had been irradiated with radiation on a starch-free salt agar medium that is commonly used for the growth of actinomycetes. This mutant strain is characterized by a smooth colony morphology (compared to the parent strain) and a lighter color tone. In addition, using genetic engineering technology, Streptparticillium rimofaciens (Engineering F0 1a6)
The gene governing the 5-hydroxymethylcytosine production activity of 92) was cloned into bacteria other than actinomycetes such as Escherichia coli, or yeast, and these bacteria or yeast were found to have 6-hydroxymethylcytosine production activity. If necessary, these microorganisms can also be used for the purpose of carrying out the present invention.

6−ヒドロキシメチA/S/)シンの製造に用いられる
培地としては、一般に微生物が同化しうる戻素源、ff
l素源および無−撫、要すれば微量栄養素。
The culture medium used for the production of 6-hydroxymethycin A/S/) generally contains a return element source that can be assimilated by microorganisms, ff
Sources of nutrients and micronutrients, if necessary.

発育促進因子などの微量有効物質が用いられる。Trace amounts of active substances such as growth-promoting factors are used.

すなわち脚素源としては、たとえばグルコース。In other words, as a leg element source, for example, glucose.

vユpロース、si蜜、でんぷん、デキストリン。vYup loin, honey, starch, dextrin.

グリセリン、ソルビットなどが用いられ、また窒素源と
しては、たとえば肉エキス、大豆粉、コーン・ステイー
ドリカー、カゼイン、ペプトン。
Glycerin, sorbitol, etc. are used, and nitrogen sources include, for example, meat extract, soybean flour, corn stay liquor, casein, and peptone.

綿寮粕などの有嶺窒素源のほか、アンモニウム塩。In addition to natural nitrogen sources such as cotton lees, ammonium salts.

硝酸塩などの無機樵が用いられ、これらは単独もしくは
組合せて使用される。
Inorganic substances such as nitrates are used, either alone or in combination.

さらに6−ヒドロキシメチルシトシンの生成を顕著に促
進するために1培地に化合物工に示されるyトVン誘導
体を添加して培費するのがよい。
Furthermore, in order to significantly promote the production of 6-hydroxymethylcytosine, it is preferable to add a yton derivative shown in Compound Engineering to one medium.

このような化合物としては、式(I)におけるRが水素
であるような化合物、すなわちシトシン。
Such compounds include compounds in which R in formula (I) is hydrogen, ie, cytosine.

VチジンまたはVチs)A/酸などのほか、それらを含
む核rIat九はその加水分解物あるいは轍生物菌体、
農畜水°産資源などが用いられる。Rがノ\ロゲン原子
であるような化合物、すなわち5−ノ蔦ロゲノシトシン
、5−ハロゲノシチジンまたは6−バロゲノシチジμ酸
なども本発明の目的に用いられる。Rがアμキル基の場
合、すなわち5−アμキルシFシン、5−ア〃キA/V
チジンあるいは6−ア〜キiW5/チジ〃酸なども用い
られる。このよりなシ)F:/ii導体を培地に添加す
る場合、添加濃度は通常Q、 5 m M以上、望まし
くは1mM〜100mM(ミリモル濃度1型量/容量)
、より望ましくは3mM〜60mM(ミリモル濃度1重
1/容量]゛が適当である。これらを培地に添加する時
期としては、培養開始以前に加えるのがもつとも有効で
あるが、培養途中において連続的または間歇的に添加し
てもよい。
In addition to V-tidine or V-tis) A/acid, nuclear rIat9 containing them is a hydrolyzate thereof or a fungal cell of a rut organism,
Agricultural, livestock, and aquatic resources are used. Compounds in which R is a norogen atom, such as 5-notologenocytosine, 5-halogenocytidine or 6-valogenocytidic acid, are also useful for the purpose of the present invention. When R is a μkyl group, i.e., 5-μkyl F syn, 5-akyl A/V
Tidine or 6-a-iW5/thidic acid can also be used. When adding F:/ii conductor to the culture medium, the addition concentration is usually Q, 5 mM or more, preferably 1mM to 100mM (millimolar concentration type 1 amount/volume).
, more preferably 3mM to 60mM (mimolar concentration 1 weight 1/volume).As for when to add these to the medium, it is most effective to add them before the start of culture, but it is effective to add them continuously during the culture. Alternatively, it may be added intermittently.

本発明に用いられる微生物を培養する方法としては、表
面培養法によってもよいが、通常、深部通気攪拌培養法
によるのが合理的である。深部培養法による場合、培地
の液性は中性ないし微酸性もしくは轍アμカリ性が好ま
しく、また培養の温度は、16ないし40℃、とりわ1
24ないし84℃に保つのが望ましい。しかしこれ、ら
O培養条件は使用する微生物の種類や外部の条件などに
応じて、好ましい結果が得られるように適宜選択するこ
とができることは言うまでもない。通常このような条件
で4日ないし14日培養すれば、5−ヒドロキシメチル
シトシンは培養物中に著量蓄積される。得られた培養物
から5−ヒドロキジメチ/I/S/)$/ンを採取する
にあたっては、核酸塩基を微生物の培養物中から採取す
るのに通常用いられる分離、採取の手段が適宜組合せて
使用される。
As a method for culturing the microorganisms used in the present invention, a surface culture method may be used, but it is usually rational to use a deep aeration agitation culture method. When using the deep culture method, the liquid nature of the medium is preferably neutral to slightly acidic or slightly alkaline, and the culture temperature is 16 to 40°C, especially 1.
It is desirable to maintain the temperature between 24 and 84°C. However, it goes without saying that the culture conditions can be appropriately selected depending on the type of microorganism used, external conditions, etc. so as to obtain preferable results. Normally, if the culture is carried out under such conditions for 4 to 14 days, a significant amount of 5-hydroxymethylcytosine will be accumulated in the culture. To collect 5-hydroxydimethy/I/S/)$/n from the resulting culture, an appropriate combination of separation and collection methods commonly used to collect nucleobases from microbial cultures is used. be done.

たとえばまず濾過、遠心分離などの手段によって菌体を
除去する。得られた上清液を適宜の吸着剤。
For example, first, bacterial cells are removed by means such as filtration or centrifugation. Transfer the resulting supernatant to an appropriate adsorbent.

たとえば活性度、吸着性樹脂、陽イオン交換樹脂。For example, activity, adsorptive resins, cation exchange resins.

活性アルミナ、シリカゲルあるいは分子−の如き吸着剤
と接触させて目的物質を吸着させたのち、たとえばアセ
トン、メタノ−〃、エタノール、プロパツール、ブタノ
−μ゛などの水溶性有−溶謀の含水液、あるいは酸、ア
1v−13y、緩衝液もしくは無機塩、有嶺墳の水溶液
を溶剤として、目的物質會溶離することができる。これ
らの分離手段を適宜組合せて実施したのち、有効−分を
濃縮して沈澱させれば6−ヒドロキシメチルシトシンを
遊離の伏−もしくは樵の伏線で採取することができる。
After adsorbing the target substance by contacting it with an adsorbent such as activated alumina, silica gel or molecules, it is then adsorbed with a water-containing liquid such as acetone, methanol, ethanol, propatool, butano, etc. Alternatively, the target substance can be eluted using an acid, a 1v-13y, a buffer solution, an inorganic salt, or an aqueous solution of Arine as a solvent. After performing these separation methods in an appropriate combination, the effective fraction is concentrated and precipitated, and 6-hydroxymethylcytosine can be collected in the free form or in the form of woodcutter.

6−ヒドロキシメチfi/¥トンンは、たとえば抗生物
質ミルデイオマイVンの製造法(特開昭56−8249
5号公報)において、培地に含有させることによりミμ
デイオ!イシンの生産量を増大させる効果を有する。
6-Hydroxymethyfi/¥ton can be used, for example, in the method for producing the antibiotic mildeiomycin (Japanese Patent Application Laid-Open No. 56-8249
No. 5), by including it in the culture medium, micro
Deio! It has the effect of increasing the production amount of isin.

以下に*施例をあげて本発明の内容をさらに詳細に説明
するが、本例は本発明の実施一様の一例である仁とは言
うまでもない。
The content of the present invention will be explained in more detail with reference to *Example below, but it goes without saying that this example is just an example of how the present invention can be carried out.

く実施例1〉 21容坂ロフラスコにグ〃コース1%、#母エキスO1
s%、ペプトンO6%(重量/容量)からなる培地60
0−を20%苛性ソーダ水溶液でpH7に#1整した後
に分注、滅菌し、これにストン1ドパーテイシリウムQ
リモフアシエンス(Streptoverticill
ium  rj−mofaci、ens)工FO1a 
692 (FERM−P Nl 2549.  ATC
O81120)の斜面培養物を接種したのち、28℃で
48時間往復振盪培養機上で培養した。50111鉢4
’llにグルコース8%、コーン・ステイープ・リカー
2%、硫酸アンモニウムo、is、硫酸マグネシウム0
.05%、10フロ(トレーター嗜オイ〜・ミル社il
!りif脚酸炭酸カルシウム8%(重量/容量)からな
る培地aOgを20%苛性ソーダ水溶液でpH7に調整
、滅菌し、先に培養した坂ロフラスコ培養液500 m
lを接種し、通気量l VVM (単位液容量当りの毎
分の通気容量)、攪拌ii1転数16 orpmで28
℃、24時間培養して櫨培費とした。2001容発酵櫓
にグルコース12%、カゼインa%、コーン・ステイー
プ・リカー0.6%、プロフロ(トレーダー・オイル・
ミル社m)2%、硝酸アンモニウム0゜5%、硫酸アン
+=?A0.5% 、硫酸IJNlk0.006% 、
Wt酸マンガン0.005%、炭酸カルシウムl−およ
び若干の消泡剤からなる培地10011を調製し、これ
にシトシン100Fを加えたのち、滅菌して、前記の種
培養液101を移植し、通気量Q、5VVM。
Example 1〉 In a 21-volume slope flask, 1% glucose, #mother extract O1
s%, peptone O 6% (weight/volume) medium 60
0- was adjusted to pH 7 with a 20% aqueous solution of caustic soda, dispensed and sterilized, and then added Stone 1 doparticillium Q.
Streptoverticill
ium rj-mofaci, ens) ENGFO1a
692 (FERM-P Nl 2549. ATC
O81120) was inoculated and cultured on a reciprocating shaker incubator at 28°C for 48 hours. 50111 pot 4
'll with 8% glucose, 2% corn steep liquor, ammonium sulfate o, is, magnesium sulfate 0
.. 05%, 10 flo
! If a culture medium aOg consisting of 8% calcium carbonate (weight/volume) is adjusted to pH 7 with a 20% aqueous solution of caustic soda and sterilized, 500 m of the previously cultured Sakaro flask culture solution is added.
inoculated with l, aeration volume l VVM (ventilation volume per minute per unit liquid volume), agitation II 1 revolution at 16 orpm and 28
The cells were cultured at ℃ for 24 hours and used as a culture medium. 2001 volume fermenter with 12% glucose, a% casein, 0.6% corn steep liquor, Proflo (Trader Oil)
Mill Co. m) 2%, ammonium nitrate 0゜5%, ammonium sulfate +=? A0.5%, sulfuric acid IJNlk0.006%,
A medium 10011 consisting of 0.005% Wt manganese acid, calcium carbonate l-, and some antifoaming agent was prepared, and after adding cytosine 100F to it, it was sterilized, the seed culture solution 101 was transplanted, and the aeration was carried out. Quantity Q, 5VVM.

攪拌回転数20Orpm、温度28℃で5日間培養した
Culture was carried out for 5 days at a stirring rotation speed of 20 rpm and a temperature of 28°C.

かくして得られ九培養液からaOlをとり、これに水2
ONとハイフロス−パー七ル(ジミンズ・マンビル社製
)1&gを加えて濾過し461の炉液を得、濃塩酸を滴
下してpHを2に調整した。これを6gのクロマトグツ
フィー用活性決(式日薬品製)を充填したカラムに通液
した。カラムを20eの水で洗ったのち、n−ブタノ−
〃飽和水101を用いて溶出し、有効画分を集め、6g
のイオン交換樹脂アンバーライトエR−120(ローム
・アンド・ハース社製)HWのカラムに通じて、カラム
’に201の水で洗浄後、a%アン毫ニア水で溶出した
。溶出液の有効両分を集めて、減圧下に濃縮し、11の
濃縮液を得た。これを20gの分子篩、セファデックス
G−10(ファルマシア社製)を充填したカラムに通液
し水を用いて溶出し丸。活性−分を集め減圧濃縮をして
0.51の濃縮液を得、これをイオン交換樹脂アンバー
ライトCG−50(ロームΦアンF9ハ―ス社製)NH
”型21を充填したカラムに通じ、有効画分を流出し丸
。有効−分を減圧濃縮し、0.151!まで濃縮すると
白色の針状結晶が析出した。これを集めて乾燥し、6−
ヒドロキシメチ〃シトシン51Fを4た。
Take aOl from the thus obtained culture solution and add 2 ml of water to it.
ON and 1 g of Hyflo-Spar7al (manufactured by Jimins Manville) were added and filtered to obtain a solution of 461, and concentrated hydrochloric acid was added dropwise to adjust the pH to 2. This solution was passed through a column packed with 6 g of chromatography active solution (manufactured by Shikinichi Pharmaceutical Co., Ltd.). After washing the column with 20e of water, add n-butano-
〃Elute using saturated water 101, collect the effective fraction, 6g
The mixture was passed through a column of ion exchange resin Amberlite R-120 (manufactured by Rohm and Haas) HW, and the column was washed with 201% water and eluted with a% ammonia water. Both effective portions of the eluate were collected and concentrated under reduced pressure to obtain 11 concentrates. This was passed through a column packed with 20 g of molecular sieve and Sephadex G-10 (manufactured by Pharmacia) and eluted with water. The active components were collected and concentrated under reduced pressure to obtain a concentrated solution with a concentration of 0.51, which was then treated with ion exchange resin Amberlite CG-50 (Rohm Φ Anne F9 manufactured by Haas Co., Ltd.) NH
The effective fraction was passed through a column packed with Type 21, and the effective fraction was poured out into a round shape.The effective fraction was concentrated under reduced pressure to 0.151!, and white needle-like crystals were precipitated. −
4 hydroxymethycytosine 51F.

〈実施例2〉 9!施例1の方法で培養するとき、培地にシトシンを加
えない場合ならびに種々の濃度で添加し九場合の6−ヒ
ドロキンメチルシトシンの生成量を定量し、表IK水す
結果を得た。
<Example 2> 9! When culturing according to the method of Example 1, the amount of 6-hydroquinemethylcytosine produced was determined when cytosine was not added to the medium and when cytosine was added at various concentrations, and the results shown in Table IK were obtained.

表1 く実施例aン 実施例1の方法で培養するとき、培地にシトシンt−加
、する代りに5−フルオロVトシン、5−ブロモシトシ
ンt 5−g−ドシトVン、5−メチルシトシンを二種
類の濃度で培地に添加して培養し、培養物中に蓄積され
たら一ヒドロキシメチルシトシンを定量したところ、表
2に示す結果が得られ友。
Table 1 When culturing according to the method of Example 1, cytosine was added to the medium, and instead of adding 5-fluoroV-tosine, 5-bromocytosine, 5-g-docytosine, 5-methylcytosine. When cultured with two different concentrations of monohydroxymethylcytosine added to the culture medium, monohydroxymethylcytosine was quantified once it had accumulated in the culture, and the results shown in Table 2 were obtained.

表2 く来施@4〉 実施例8の方法で培養するとき、培養に用いる一株をス
トレプトパーティシリウム・リモファシエンX (St
reptoverticillium rimofac
iens)工F O1a 592 (FERM−P凪2
549)の代シに、ストレプトパーティシリウム・リモ
ファシ:c y p−(Streptovertici
liium rimofaciens )工F 0 1
4126 (FERM−P Na 6052−)を用い
て培養し表8に示す結果を得た。
Table 2 Kukuruse@4〉 When culturing according to the method of Example 8, one strain used for culture is Streptparticillium rimofaciens X (St
reptoverticillium rimofac
iens) Engineering F O1a 592 (FERM-P Nagi2
549), Streptparticillium rimofasi:cyp-(Streptovertici
liium rimofaciens) engineering F 0 1
4126 (FERM-P Na 6052-) was used to obtain the results shown in Table 8.

表8 上記の実施例1.2.1.4で得られた6−ヒFロキV
メチルシトシンは、アレグリア(Aleg −ria 
)の方法〔ビオケミカ拳エトービオフイジカや7クタ(
Biochemica  et  Bxophyslc
aActa)、第149巻817−824頁、 (19
67年)〕にもとづいて合成された5−ヒドロキシメチ
ルシトシン標品およびシグマ社製市販試薬の5−ヒドロ
キシメチルV)シンと物理化学的性状が完全に一致した
。すなわち元素分析、ペーパークロマトグフフイーRf
値、紫外部吸収スベクトフム、核磁気共鳴スペクトツム
を以下にボす。
Table 8 6-Hyfurokki V obtained in Example 1.2.1.4 above
Methylcytosine is present in Alegria (Aleg-ria).
) method
Biochemica et Bxophyslc
aActa), Vol. 149, pp. 817-824, (19
The physicochemical properties of the 5-hydroxymethylcytosine sample synthesized based on 1967) and the 5-hydroxymethylcytosine commercially available reagent manufactured by Sigma Co., Ltd. were completely identical. Namely, elemental analysis, paper chromatography Rf
The values, ultraviolet absorption spectrum, and nuclear magnetic resonance spectrum are listed below.

(1)元素分析値 元素分析値g C−42,54%、H−5,00%、N
=29、78% (2)ペーパークロマトグフフイー ペーパークロマトグフフイーRf値は表4に一帖して示
した。
(1) Elemental analysis value Elemental analysis value g C-42,54%, H-5,00%, N
=29, 78% (2) Paper chromatography Paper chromatography Rf values are shown in Table 4.

表4 ペーパークロマトグフフイーRf値秦・・・容量
混合比 (3)紫外部吸収スペクトフム ’5AoN NaoH,MoN )4C1をそれぞれ溶
剤とし九場合のスペクトラムを得、その極大吸収波長お
よび極小吸収波長ならびに250nmと260nmにお
ける吸収値の比および280nmと260nmにおける
吸収値の比を表6にボした。
Table 4 Paper chromatograph Rf value Qin Capacity mixing ratio (3) Ultraviolet absorption spectrum (3) Ultraviolet absorption spectrum (NaoH, MoN) 4C1 was obtained as a solvent, and its maximum absorption wavelength, minimum absorption wavelength, and 250 nm were obtained. Table 6 shows the ratio of absorption values at 280 nm and 260 nm and the ratio of absorption values at 280 nm and 260 nm.

(以下余白) (4)核磁気共鳴スペクトラム 重水中で測定した130−NMRスペクトラムから得ら
れるI値(ppm)を表6に示した。
(Margin below) (4) Nuclear Magnetic Resonance Spectrum I values (ppm) obtained from the 130-NMR spectrum measured in heavy water are shown in Table 6.

(以下余白)(Margin below)

Claims (1)

【特許請求の範囲】[Claims] (1)ストレグドパ−ティシリウム属に属する6−ヒド
ロキンメチA/S/)シン生産菌を培地に培養し、培養
物中に6−ヒドロキシメチA/F)シンを生成蓄積せし
め、これを採取することを特徴とする6−ヒドロキシメ
チルシトシンの製造法。 (式中、Rは水素、ハロゲンまたは低級アルキルを示す
)で表わされる化合物を含有する培地を用いる特許請求
の範囲第1項記載の製造法。
(1) Cultivating 6-hydroxymethyA/S/)sin-producing bacteria belonging to the genus Streggedparticillium in a medium, producing and accumulating 6-hydroxymethysA/F)syn in the culture, and collecting it. Characteristic method for producing 6-hydroxymethylcytosine. 2. The production method according to claim 1, which uses a medium containing a compound represented by the formula (wherein R represents hydrogen, halogen, or lower alkyl).
JP14717481A 1981-09-17 1981-09-17 Preparation of 5-hydroxymethylcytosine Granted JPS5847497A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14717481A JPS5847497A (en) 1981-09-17 1981-09-17 Preparation of 5-hydroxymethylcytosine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14717481A JPS5847497A (en) 1981-09-17 1981-09-17 Preparation of 5-hydroxymethylcytosine

Publications (2)

Publication Number Publication Date
JPS5847497A true JPS5847497A (en) 1983-03-19
JPS6360997B2 JPS6360997B2 (en) 1988-11-28

Family

ID=15424250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14717481A Granted JPS5847497A (en) 1981-09-17 1981-09-17 Preparation of 5-hydroxymethylcytosine

Country Status (1)

Country Link
JP (1) JPS5847497A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103091492A (en) * 2011-11-04 2013-05-08 中国科学院上海生命科学研究院 Diagnostic reagent and kit for cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103091492A (en) * 2011-11-04 2013-05-08 中国科学院上海生命科学研究院 Diagnostic reagent and kit for cancer

Also Published As

Publication number Publication date
JPS6360997B2 (en) 1988-11-28

Similar Documents

Publication Publication Date Title
Vollbrecht et al. Excretion of metabolites by hydrogen bacteria: III. D (−)-3-hydroxybutanoate
EP0547898A2 (en) Microbial process for the production of trans-4-hydroxy-L-proline
JPS5847497A (en) Preparation of 5-hydroxymethylcytosine
CN114875093A (en) Method for improving fermentation yield of PF1022A
JPS6030679A (en) Preparation of s-adenosyl-l-homocysteine hydrolase
JPS5920359B2 (en) Production method of polylysine
KR810000509B1 (en) Process for the preparation of single cell protein
JPS62126990A (en) Production of sedoheptulose
Pancholy Microbial formation of carcinogenic dimethylnitrosamine
JPH05137572A (en) Thermostable adenosine-5&#39;-triphosphate sulfurylase and its production
JPS6057833B2 (en) Method for producing L-tryptophan
JPS6117475B2 (en)
SU675986A1 (en) Starhylococcus saprophyticush 1 strain as urease producent
RU2078138C1 (en) Strain of bacterium arthrobacter globiformis - a producer of coproporphyrin-iii and a method of coproporphyrin-iii preparing
JPS6038116B2 (en) Method for producing phenylphenols
JPS6122956B2 (en)
JPS58216689A (en) Novel phosphorus-containing compound and its preparation
JPS6147194A (en) Preparation of n-carbamoyl-d-valine or d-valine
JPS62210996A (en) Production of antibiotic substance emimycin
JPS6240298A (en) Production of optically active dibromopropanol by treatment with microorganism
JPS5934891A (en) Preparation of azaserine by fermentation
RU95107036A (en) Method of production of microbiological preparations
JPH01187091A (en) Production of d-alanine by fermentation method
JPS62130694A (en) Production of pyrroloquinolinequinone labelled 14c
JPS59173089A (en) Preparation of l-threo-beta-hydroxyaspartic acid